Introduction
Materials and methods
Patients and specimens
Without recurrence/metastasis | With recurrence/metastasis |
P
| |
---|---|---|---|
N
| 56 | 91 | |
Age (years) | 50.8 ± 12.8 (13.0-77.0) | 52.2 ± 12.4 (15.0-81.0) | 0.510 |
Tumor size (cm) | 3.2 ± 1.9 (1.2-9.5) | 3.0 ± 1.6 (0.4-8.2) | 0.437 |
Lymph node involvement | 45 (80.4%) | 70 (76.9%) | 0.624 |
TNM stages | |||
I | 5 (8.9%) | 9 (9.9%) | 0.511 |
II | 24 (42.9%) | 32 (35.2%) | |
III | 27 (48.2%) | 49 (53.8%) | |
IV | 0 (0.0%) | 1 (1.1%) | |
ER expression | 26 (46.4%) | 31 (34.1%) | 0.168 |
PR expression | 28 (50.0%) | 36 (39.6%) | 0.266 |
Her2 expression | 29 (51.8%) | 41 (45.1%) | 0.471 |
Basal-like feature* | 9 (16.1%) | 30 (33.0%) | 0.018 |
Recurrence | 40 (44.0%) | ||
Metastasis | |||
Skin | 2 (2.2%) | ||
Lung | 20 (22.0%) | ||
Liver | 8 (8.8%) | ||
Bones | 11 (12.1%) | ||
Brain | 5 (5.5%) | ||
Others | 5 (5.5%) |
Immunohistochemical staining and evaluation
Statistical analysis
Results
Patient characteristics
Presence of CD44+/CD24- phenotype in invasive ductal carcinoma tissue
n
| All cases (%) |
P
|
n
| Recurrence/metastatic cases (%) |
P*
| |
---|---|---|---|---|---|---|
Age (years) | ||||||
< 50 | 74 | 18.34 ± 2.70 | 0.444 | 34 | 24.91 ± 3.79 | 0.022 |
≥ 50 | 73 | 15.45 ± 2.66 | 38 | 13.20 ± 3.32 | ||
Tumor size | ||||||
T1 | 47 | 15.78 ± 2.86 | 0.224 | 15 | 13.19 ± 3.53 | |
T2 | 76 | 20.12 ± 2.90 | 44 | 23.78 ± 3.68 | ||
T3 + T4 | 17 | 10.27 ± 4.46 | 13 | 11.83 ± 6.60 | 0.152 | |
Lymph node involvement | ||||||
Absent | 32 | 8.66 ± 2.70 | 0.026 | 18 | 10.00 ± 3.77 | 0.075 |
Present | 115 | 19.20 ± 2.29 | 54 | 21.53 ± 3.19 | ||
TNM stage | ||||||
I + II | 70 | 15.87 ± 2.63 | 0.500 | 33 | 16.88 ± 3.74 | 0.368 |
III + IV | 77 | 18.49 ± 2.81 | 39 | 21.73 ± 3.79 | ||
ER expression | ||||||
Negative | 90 | 16.49 ± 2.47 | 0.845 | 47 | 18.92 ± 3.17 | 0.944 |
Positive | 57 | 17.26 ± 3.07 | 25 | 19.32 ± 4.81 | ||
PR expression | ||||||
Negative | 83 | 13.09 ± 2.41 | 0.038 | 43 | 14.63 ± 3.06 | 0.046 |
Positive | 64 | 21.06 ± 2.98 | 29 | 25.32 ± 4.51 | ||
Her2 expression | ||||||
Negative | 77 | 16.18 ± 3.03 | 0.566 | 38 | 17.36 ± 4.17 | 0.441 |
Positive | 70 | 18.47 ± 2.61 | 34 | 21.57 ± 3.47 | ||
Basal-like feature † | ||||||
Absent | 108 | 18.44 ± 2.24 | 0.143 | 49 | 11.70 ± 4.07 | 0.050 |
Present | 39 | 11.93 ± 3.66 | 23 | 22.66 ± 3.30 | ||
Recurrence or metastasis | ||||||
Absent | 75 | 14.26 ± 2.72 | 0.246 | |||
Present | 72 | 18.73 ± 2.58 | ||||
Lesions in recurrence/metastatic patients | ||||||
Primary | 56 | 15.39 ± 2.63 | 0.014 | |||
Secondary | 16 | 30.41 ± 6.46 |
Association of CD44+/CD24- phenotype with steroid receptor status
Association of CD44+/CD24- phenotype with basal-like feature
Association of CD44+/CD24- phenotype with DFS and OS: univariate analysis and multivariate analysis
Variable | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | |
CD44+/CD24-/low tumor cells | ||||||
High | 2.144 | 1.321-3.479 | 0.002 | 1.963 | 1.163-3.313 | 0.012 |
Low | 1.000 | 1.000 | ||||
ER status | ||||||
Positive | 0.826 | 0.524-1.304 | 0.412 | 1.425 | 0.731-2.776 | 0.298 |
Negative | 1.000 | 1.000 | ||||
PR status | ||||||
Positive | 0.500 | 0.312–0.800 | 0.004 | 0.192 | 0.088–0.420 | 0.001 |
Negative | 1.000 | 1.000 | ||||
Her2 status | ||||||
Positive | 0.966 | 0.614–1.521 | 0.882 | 0.692 | 0.317–1.513 | 0.357 |
Negative | 1.000 | 1.000 | ||||
Basal-like feature* | ||||||
Present | 2.731 | 0.461-1.393 | 0.007 | 3.902 | 1.402-10.859 | 0.009 |
Absent | 1.000 | 1.000 | ||||
TNM stage | ||||||
Stage III/IV | 1.989 | 0.814–2.626 | 0.029 | 1.820 | 1.051–3.151 | 0.033 |
Stage I/II | 1.000 | 1.000 | ||||
Lymph node involvement | ||||||
Absent | 0.724 | 0.427-1.227 | 0.230 | 1.081 | 0.540-2.164 | 0.827 |
Present | 1.000 | 1.000 | ||||
Age (years) | ||||||
≥ 50 | 1.047 | 0.681–1.610 | 0.883 | 1.062 | 0.627–1.799 | 0.822 |
< 50 | 1.000 | 1.000 |
Variable | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | |
CD44+/CD24-/low tumor cells | ||||||
High | 2.193 | 1.383-3.477 | 0.001 | 2.237 | 1.345-3.720 | 0.002 |
Low | 1.000 | 1.000 | ||||
ER status | ||||||
Positive | 0.757 | 0.488-1.175 | 0.215 | 1.164 | 0.585-2.314 | 0.665 |
Negative | 1.000 | 1.000 | ||||
PR status | ||||||
Positive | 0.702 | 0.457–1.078 | 0.106 | 0.968 | 0.496–1.888 | 0.924 |
Negative | 1.000 | 1.000 | ||||
Her2 status | ||||||
Positive | 0.932 | 0.605–1.435 | 0.748 | 1.583 | 0.782–3.201 | 0.201 |
Negative | 1.000 | 1.000 | ||||
Basal-like feature* | ||||||
Present | 0.608 | 0.389-0.949 | 0.029 | 0.342 | 0.131-0.891 | 0.028 |
Absent | 1.000 | 1.000 | ||||
TNM stage | ||||||
Stage III/IV | 1.614 | 1.055–2.470 | 0.027 | 1.652 | 1.014–2.690 | 0.044 |
Stage I/II | 1.000 | 1.000 | ||||
Lymph node involvement | ||||||
Absent | 0.891 | 0.528-1.504 | 0.666 | 0.674 | 0.343-1.323 | 0.251 |
Present | 1.000 | 1.000 | ||||
Age (years) | ||||||
≥ 50 | 1.110 | 0.735–1.676 | 0.621 | 1.384 | 0.847–2.260 | 0.194 |
< 50 | 1.000 | 1.000 |